@valcohranmd saves the day w #MedTweetorial 🧵
💪Get best practice ℹ4 adults & peds
w @DCharabaty & @BonumCe
🏆#CME ℹ️http://bit.ly/3Hgnpcf
Supported by an edu grant from @TakedaPharma
Where r u in your career?👇
21/#ICYMI #MondayNightIBD #ShortBowelSyndrome #MedTweetorial
💡 Focus: Pharmacologic Treatment
---
RT @MondayNightIBD
1/🏋️♀️Navigating tx for pts w #ShortBowelSyndrome is hard
@valcohranmd saves the day w #MedTweetorial 🧵
💪Get best practice ℹ4 adults & peds
w @DCharabaty & @BonumCe
🏆#CME ℹ️http://bit.ly/3Hgnpcf
Supported by an edu grant from @TakedaPharma
Where r u in your career?👇
https://twitter.com/MondayNightIBD/status/1617629375826120705
20/#ICYMI #MondayNightIBD #ShortBowelSyndrome #MedTweetorial
💡 Focus: #ParenteralNutrition
---
RT @MondayNightIBD
1/📇Draw the rt cards #ParenteralNutrition #ShortBowelSyndrome w @valcohranmd @DCharabaty
#MNIBDTweetorial🧵
❤️PN Goals
♠️Dependence
♦️Complications
♣️Weaning, QoL +++
🏆#CME ℹ️http://bit.ly/3SZrpB4
Supported by an edu grant from @TakedaPharma
Where r u in your career?👇
https://twitter.com/MondayNightIBD/status/1579581166860275712
10/#ICYMI #MondayNightIBD #ShortBowelSyndrome #MedTweetorial
💡 Focus: #ParenteralNutrition
---
RT @MondayNightIBD
1/📇Draw the rt cards #ParenteralNutrition #ShortBowelSyndrome w @valcohranmd @DCharabaty
#MNIBDTweetorial🧵
❤️PN Goals
♠️Dependence
♦️Complications
♣️Weaning, QoL +++
🏆#CME ℹ️http://bit.ly/3SZrpB4
Supported by an edu grant from @TakedaPharma
Where r u in your career?👇
https://twitter.com/MondayNightIBD/status/1579581166860275712
9/#ICYMI #MondayNightIBD #ShortBowelSyndrome #MedTweetorial
💡 Focus: Pharmacologic Treatment
---
RT @MondayNightIBD
1/🏋️♀️Navigating tx for pts w #ShortBowelSyndrome is hard
@valcohranmd saves the day w #MedTweetorial 🧵
💪Get best practice ℹ4 adults & peds
w @DCharabaty & @BonumCe
🏆#CME ℹ️http://bit.ly/3Hgnpcf
Supported by an edu grant from @TakedaPharma
Where r u in your career?👇
https://twitter.com/MondayNightIBD/status/1617629375826120705
Speaking of catching up on #TumorBoardTuesday’s 𝗙𝗥𝗘𝗘 CME, we’ll add a couple of awesome threads 🧵 from the last week you may have missed.
⏪ Rewind ⏪ to last week’s excellent deep dive 🤿 tweetorial from @DrMMurphy @MeganLeigh127 on #EndometrialCancer
---
RT @TumorBoardTues
1/#OncTwitter #TumorBoardTuesday #MedTweetorial 🧵
✅#EndometrialCancer AE deep dive🤿
🧪Trial results
🔬Tox for TKI-ICI
w @DrMMurphy @MeganLeigh127 & us!
🆓#CME @…
https://twitter.com/TumorBoardTues/status/1615518555717656576
3/#TumorBoardTuesday #gyncsm #OncTwitter
🤔Missed the #EndometrialCancer #MedTweetorial earlier this wk?
🤯Feeling left behind?
Don't fret, it's here📍
---
RT @BonumCe
1/ #OncTwitter #TumorBoardTuesday
✅#EndometrialCancer #MedTweetorial🧵
w @DrMMurphy @MeganLeigh127 @TumorBoardTues
🧬Tx response
🧪Trial results
🔬Tox for TKI-ICI
🆓#CME 🔗 http://bit.ly/3VBGJEJ
Supported by educational grants from Eisai & @Merck
https://twitter.com/BonumCe/status/1615519240542646275
In partnership with Tumor Board Tuesday, this CME-certified, Tweetorial reviews the latest data related to anti-angiogenic therapies and immune checkpoint inhibitors in Endometrial Carcinoma (EC). An assessment of associated toxicities of these agents will lead learners to evaluate how these toxicit
In partnership with Tumor Board Tuesday, this CME-certified, Tweetorial reviews the latest data related to anti-angiogenic therapies and immune checkpoint inhibitors in Endometrial Carcinoma (EC). An assessment of associated toxicities of these agents will lead learners to evaluate how these toxicit
1/#OncTwitter #TumorBoardTuesday #MedTweetorial 🧵
✅#EndometrialCancer AE deep dive🤿
🧪Trial results
🔬Tox for TKI-ICI
w @DrMMurphy @MeganLeigh127 & us!
🆓#CME @BonumCe🔗http://bit.ly/3VBGJEJ
Supported by edu grants from Eisai & @Merck
🟢What's your specialty?
In partnership with Tumor Board Tuesday, this CME-certified, Tweetorial reviews the latest data related to anti-angiogenic therapies and immune checkpoint inhibitors in Endometrial Carcinoma (EC). An assessment of associated toxicities of these agents will lead learners to evaluate how these toxicit
9/#TumorBoardTuesday #OncTwitter #NephTwitter #BonumCE
#ICYMI 🪡#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann
🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt
---
RT @TumorBoardTues
1/ #OncTwitter #NephTwitter #TumorBoardTuesday
✅#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann
🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt
🆓#CME @BonumCe🔗http://bit.ly/3VDaK81
Support by edu grants from Eisai…
https://twitter.com/TumorBoardTues/status/1602468719426342913
In partnership with Tumor Board Tuesday, this CME-certified, Tweetorial reviews the latest data related to anti-angiogenic therapies and immune checkpoint inhibitors in Renal Cell Carcinoma (RCC). An assessment of associated toxicities of these agents will lead learners to evaluate how these toxicit